원료 사전 탐색/lactic-acid/LACTIC ACID
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
합성 (Synthetic)

LACTIC ACID

식약처 한글 표준명: 락틱애씨드
pH조절제보습제피부컨디셔닝제완충제
[식약처 공정서 기원 및 정의] 이 원료는 다음의 구조를 갖는 유기산이다.
결론 선행 Executive Regulatory & Safety Fact BoxAEO / GEO CITATION ANCHOR

화장품에서 락틱애씨드 (LACTIC ACID)의 글로벌 배합 한도와 핵심 효능·처방 기준은 무엇인가요?

락틱애씨드(표준 INCI: LACTIC ACID, CAS 번호: 50-21-5)은 화장품 처방에서 주로 pH조절제, 보습제, 피부컨디셔닝제 목적으로 배합되는 핵심 원료입니다. 한국 식약처(미규제) 및 유럽 CosIng(미규제) 등 6대 권역 법정 기준 하에 관리되며, 통상 0.1–0.9%(적정 pH 4–8) 범위에서 안정적으로 처방됩니다.

7대 갈래 국가별·용도별 공식 전성분 라벨 표기명 매트릭스

각국 1차 법원 고시 정본 · 기계번역·임의 음차 0건
7-Track Official Statutory Label Names for LACTIC ACID
국가·규제 트랙공식 고시 전성분 표기명원클릭 복사
① 한국 (MFDS 화장품 한글 표준명)락틱애씨드
② 한국 구명칭 (개정 전 이력 · 301 리다이렉트)——
③ 유럽 (EU CosIng EC 1223/2009)LACTIC ACID
④ 미국 일반화장품 (US PCPC / MoCRA INCI)LACTIC ACID
⑤ 미국 OTC (FDA Active Ingredient Monograph)— (비-OTC 일반 화장품 원료)—
⑥ 중국 (NMPA IECIC 표준 중문명)乳酸
⑦ 일본 일반화장품 / 의약부외품 (JCIA / MHLW)乳酸 · [QD: 乳酸]

Layer 1 — 글로벌 6대 권역 법정 배합 한도 및 규제 상태

Layer 1 Statutory Regulatory Limits Across 6 Regions for LACTIC ACID
권역규제 상태배합 한도제한 조건 및 1차 법원 출처
한국 (MFDS)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
유럽 (CosIng)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
미국 (FDA/CIR)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
중국 (NMPA)등재·허용GMPIECIC Entry #5649
일본 (MHLW)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)
아세안 (ACD)미규제GMP공식 화장품 원료 목록 등재 (GMP 기준 사용)

Layer 2 — 독성·안전성 평가 한도 (US CIR · EU SCCS MoS≥100 · CN IECIC 최고역사사용량)

「SCCS 안전 판정 상한」은 유럽 소비자안전과학위원회가 안전역(MoS≥100)으로 판정한 상한이며, 「CIR 시판 보고 농도」와 「중국 IECIC 최고역사사용량」은 실제 시판 제품에 보고된 최대 농도입니다.

Layer 2 Toxicological & Historical Safe Use Concentrations for LACTIC ACID
안전성 평가 기준적용 부위·유형안전 농도 범위판정 결과 및 문헌 번호
중국 IECIC 최고역사사용량leave_on≤ 6%안전 판정(MoS≥100)NMPA IECIC (2025) Entry 05688 (2025)
중국 IECIC 최고역사사용량rinse_off≤ 6%안전 판정(MoS≥100)NMPA IECIC (2025) Entry 05688 (2025)
⚠️ 참조용 안내 (법적 면책 공지): 이 사전의 성분명·규제 한도·배합 가이드는 연구·개발 참조용으로만 제공됩니다. 각국 고시 개정 시차나 데이터 오기·누락이 있을 수 있으므로, 실제 제품 처방·라벨 표기·인허가 전에는 반드시 관할 기관(식약처 등)의 최신 공식 고시 원문을 직접 확인하시기 바라며, 본 사전의 정보를 잘못 사용하여 발생하는 문제에 대해 운영 주체는 법적 책임을 지지 않습니다.
제형군별 사분위수(Min–Q1–Median–Q3–Max) 분포 그래프

Layer 3 제형군별 통상 배합 농도(%) 레인지 & Layer 1 법정 한도 대조

O/W · W/O 에멀전·크림n=7
Min 0.1% · Q1 0.2% · Median 0.6% · Q3 0.75% · Max 0.9%
O/W · W/O 에멀전·크림 — 유화 로션·크림 제형 구조 형성 및 피부 컨디셔닝
공식 검증 원천: Global Starter Formulation Library Statistical Distribution (n=7, GRANT 6 · SEPPIC 1) (cir_safety) · GRANT 6 · SEPPIC 1
권장 중앙값: 0.6%

Layer 3 — 제형군별 통상 배합 농도(n≥5 사분위수) & 물리화학·상용성 가이드

Layer 3 Formulation Concentration Quartiles by Product Category for LACTIC ACID
제형군 분류Min – Q1 – Median – Q3 – Max (%)처방 역할 및 기전Source ID
제형군 B — 유화 로션 · 에멀전 · 크림 (O/W · W/O)0.1% · 0.2% · 0.6% · 0.75% · 0.9%유화 로션·크림 제형 구조 형성 및 피부 컨디셔닝Global Starter Formulation Library Statistical Distribution (n=7, GRANT 6 · SEPPIC 1)
피부 투과 과학 시각화 (Bos & Meinardi 500 Dalton Rule)MW: Macro/Complex · LogP: N/A

각질층 장벽 투과 깊이 & 바이오 스피큘 경피전달(DDS) 시뮬레이션

각질층 (Stratum Corneum · 10~20 µm)500 Dalton 장벽 (고분자·친수성 성분 차단)생존 표피층 (Viable Epidermis · 50~100 µm)멜라닌세포 · 각질형성세포 타깃 (미백·장벽·턴오버)진피 유두층 (Papillary Dermis · 150~300 µm)섬유아세포 콜라겐 I/III · 엘라스틴 · PDRN 재생 타깃표피~상부 진피 확산 (<500 Da)
분자량(MW) & 친유성(LogP) 투과 판정
저분자 영역 (320 Da ≤ 500 Da) — 각질층 수동 확산 가능

단독 도포 시 각질층 세포간 지질(Brick & Mortar) 경로를 통해 확산됩니다. 500 Dalton 이상 친수성 분자는 각질층 표면에 주로 머물러 보습·보호막 역할을 수행합니다.

예상 도달 깊이
40–90 µm
권장 전달 시스템
Polyol Enhancer / Serum
계면화학 · pH · 열역학 공정 시각화

pH 안정성 스펙트럼(0~14) · 가열 한계 게이지 · HLB 콜로이드 상거동

Water or glycol phase soluble/dispersible
적정 처방 pH 안전 윈도우 (pH 0 ~ 14 스펙트럼)pH 4.0 – 8.0
0245.5791114

권장 구간 밖(pH < 4 또는 pH > 8)에서는 가수분해·점도 저하·이온 탈리 위험이 증가합니다.

공정 가열 한계 온도 (Max Process Temp)≤ 50°C
25°C45°C60°C75°C85°C100°C

최대 50°C 가열 공정에서 열적 안정성이 유지됩니다.

계면활성·유화 HLB 스펙트럼 (0 ~ 20) & 미셀/액정 배열 시뮬레이터
O/W 수중유형 미셀 에멀전 (수분 크림·로션)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
생화학 신호전달 경로 (Biochemical Pathway Map)

세포·분자 타깃 작용 기전 플로우 다이어그램

1. 각질층·표피 작용→ 촉진·활성 (Activation)
각질층 세포간 지질 & 수분 결합 네트워크
→
경피수분손실(TEWL) 억제 및 피부결 개선
2. 염증 매개체 조절⊣ 억제·차단 (Inhibition)
외부 자극 유도 산화 스트레스(ROS) 및 사이토카인
⊣
피부 진정 및 항상성 유지
처방 온톨로지 네트워크 그래프

권장 시너지(🟢 실선) & 배합 금기·주의(🔴 점선) 인터랙티브 관계도

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ 처방 내 극단적 pH 조건 및 고농도…LACTIC ACID
노드 인터랙션 가이드

🟢 초록색 시너지 원료 노드를 클릭하면 해당 원료 모노그래프로 즉시 이동하며, 🔴 붉은색 점선 노드를 클릭하면 화학적 상충(석출·변색·실활) 메커니즘을 표시합니다.

대표 상용명 참고 (상표법 제90조 제1항 제2호 설명적 표기)
LACTIC ACID

상용명 표기는 상표법 제90조 제1항 제2호에 의거하여 연구원에게 원료 등급·규격을 설명하기 위한 참고용이며, 각 상표의 권리는 해당 원료사에 귀속됩니다.

학술·독성·제형 종합 요약 (Tier 1~3 탄력 요약)

Tier 1 Synthesis

이 원료에 매칭된 PubMed 동료심사 논문 초록과 공인 독성 보고서만으로 작성된 학술 요약입니다.

■ [1. 화학적 정체성 및 규격 (Chemical Identity & Standard Nomenclature)] - 표준명: 락틱애씨드 | INCI: LACTIC ACID | CAS No.: 50-21-5 | EC No.: 200-018-0 - 기원 및 분류: SYNTHETIC | 주요 기능: pH조절제, 보습제, 피부컨디셔닝제, 완충제 - 물리화학 스펙: 분자식 복합 조성이거나 단일 화학식 미지정 | 분자량 고분자/복합물(Polymer/Complex) | 친수/친유 밸런스 특화 | 이온성: non-ionic | CosIng/MFDS 등재 - 7대 권역 공식 라벨 표기: KR [락틱애씨드] · EU [LACTIC ACID] · US [LACTIC ACID] · CN [乳酸] · JP [乳酸] · JP의약부외품 [乳酸] ■ [2. 피부과학적 작용 기전 및 제형 내 역할 (Mechanism of Action & Function)] - 이 원료는 다음의 구조를 갖는 유기산이다. 물리화학적 분류상 기원(synthetic)에 기반하여 피부 장벽 및 제형 매트릭스 내에서 고유한 기능(pH조절제, 보습제, 피부컨디셔닝제, 완충제)을 수행하며, 계면 안정화·보습·피부 컨디셔닝 또는 유효성분 전달에 기여합니다. ■ [3. 글로벌 6대 권역 법정 규제 및 안전성 한도 (Layer 1 & Layer 2 Regulatory Matrix)] - 6개국 요약: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (중국 IECIC(2025) 등재번호 5649 (乳酸)) - 6대 주요 권역(KR·EU·US·CN·JP·ASEAN) 별도 배합금지/특수제한 고시 없음 (GMP 일반 안전 기준 내 배합 허용). - 공인 안전성·역사적 사용 농도(Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): 최대 6.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): 최대 6.0% ■ [4. 제형군별 통상 배합 가이드 (Layer 3-A Formulation Dosage Guide)] - [emulsion_cream] 권장 범위: 0.1 ~ 0.9% (중앙값 0.6%, 근거: Global Starter Formulation Library Statistical Distribution (n=7, GRANT 6 · SEPPIC 1)) — 유화 로션·크림 제형 구조 형성 및 피부 컨디셔닝 ■ [5. 연구원 공정 설계 · 안정성 · 배합 금기 (Layer 3-B Process & Compatibility)] - 투입 공정(Phase): Water Phase or Cool-down Phase (< 45°C) - 적정 pH 구간: pH 4.0 ~ 8.0 | 공정 내열 온도: 최대 50°C | 전해질(염) 내성: MEDIUM - 배합 주의/금기: 처방 내 극단적 pH 조건 및 고농도 전해질과의 상용성 사전 확인 권장 - 시너지 추천 원료: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | 참고 상용 원료명: LACTIC ACID ■ [6. 학술 논문 및 공인 문헌 근거 (Peer-Reviewed Literature & Compendia)] - PMID 42317277 (2026, Food Chem X): Deep eutectic solvent-mediated extraction of collagen peptides from sturgeon skin: Molecular-weight control and mechanis - PMID 42303762 (2026, Aesthetic Plast Surg): PLLA Microspheres Regulate Adipocyte Dedifferentiation via Lactate: A Novel Strategy for Fat Graft Survival Enhancement - PMID 42296811 (2026, J Hazard Mater): Organic acids enhanced the phototransformation of 1-nitronaphthalene in skin sweat: The critical role of carbon-centered

근거 동료심사 학술 논문 (미국 NIH PubMed) (12)

Deep eutectic solvent-mediated extraction of collagen peptides from sturgeon skin: Molecular-weight control and mechanistic insights [PMID: 42317277 · 2026]
Bai M, Wang N, Zhang M, Zhao Z, Yu J, She W, Obadina AO, Zhao Y, Li S, Wu H, Zhao T · Food Chem X (2026)

A choline-oxalic acid deep eutectic solvent (DES) was developed for the molecular-weight-controlled extraction of collagen peptides from sturgeon ( Acipenser spp.) skin, a collagen-rich fish-processing by-product containing 78.28% protein and 63.47% collagen. Among three choline-based organic-acid DESs, choline-oxalic acid exhibited the best extraction performance and produced lower-molecular-weight peptide fractions than choline-lactic acid and choline-acetic acid systems. Under the optimized conditions of 70&#xa0;&#xb0;C, a solid-to-liquid ratio of 1:80, and 2&#xa0;h, the extraction rate reached 98.45%. Time-dependent extraction enabled controllable peptide production: a 2&#xa0;h treatment mainly generated collagen polypeptides in the 1-10&#xa0;kDa range, whereas extending the reaction to 4&#xa0;h produced oligopeptides predominantly in the 0.5-1&#xa0;kDa range. For downstream recovery, isopropanol showed the highest precipitation efficiency, achieving approximately 92% peptide recovery at an extract-to-solvent ratio of 1:6. UV-Vis analysis showed a characteristic collagen peptide absorption band near 230&#xa0;nm, while FT-IR spectra displayed typical amide bands, including amide I at approximately 1630&#xa0;cm -1 and amide III at 1240-1300&#xa0;cm -1 , confirming the collagen-derived nature of the products. Molecular simulation further suggested that oxalic acid competed for backbone hydrogen bonding, while chloride ions interacted with hydroxyproline residues, as indicated by a Hyp-Cl - radial distribution peak at 0.328&#xa0;nm, promoting collagen swelling, triple-helix loosening, and controlled depolymerization. Overall, this DES-based strategy provides a rapid, tunable, and potentially sustainable route for producing collagen peptides from aquatic by-products.

PLLA Microspheres Regulate Adipocyte Dedifferentiation via Lactate: A Novel Strategy for Fat Graft Survival Enhancement [PMID: 42303762 · 2026]
Ling J, Jiang C, Li F · Aesthetic Plast Surg (2026)

Poly-L-lactic acid (PLLA) is a well-established facial filler recognized for its ability to stimulate collagen synthesis. While emerging evidence suggests that PLLA modulates the differentiation and lipolysis of dermal adipocytes, its role in autologous fat transplantation remains unclear. In vitro, mature adipocytes were treated with lactate or PLLA during ceiling culture to explore the regulatory mechanisms of PLLA-mediated dedifferentiation. Subsequently, we established a murine model of PLLA and adipose tissue co-transplantation, with grafts harvested at 7, 30, and 90&#xa0;days. Graft survival was assessed via volumetric analysis, histological evaluation, and qPCR to validate the in vitro findings. PLLA-derived lactate facilitates adipocyte dedifferentiation at low-to-moderate concentrations. This phenotypic reversion was abrogated by pharmacological inhibition of monocarboxylate transporters (MCTs). Additionally, lactate-induced DFATs exhibited enhanced angiogenic potential. In vivo, co-transplantation of PLLA and adipose tissue significantly enhanced volume retention and neovascularization. PLLA implantation triggered only a transient acute inflammatory response that stabilized subsequently without inducing chronic fibrosis, ensuring long-term biocompatibility. As a biocompatible synthetic material, PLLA degrades into lactate and enhances fat graft volume retention by promoting dedifferentiation of adipocytes. This finding indicates that PLLA holds broad application prospects in fat transplantation. This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable.

Organic acids enhanced the phototransformation of 1-nitronaphthalene in skin sweat: The critical role of carbon-centered radicals [PMID: 42296811 · 2026]
Pan W, Hou J, Tang W, Shi F, Yang J, Li Y · J Hazard Mater (2026)

Skin contact is an important route for human exposure to atmospheric pollutants. Many atmospheric pollutants possess photochemical activity, and skin sweat provides a natural environment for the photogeneration of reactive species (RSs) from pollutants. However, the photochemical transformation of atmospheric pollutants in skin sweat and their toxicological effects on the skin remain poorly understood. Herein, 1-nitronaphthalene (1-NN), a common atmospheric pollutant, was used as a model compound to investigate the influence of key components (i.e., Organic acids, Fe 3&#x202f;+ ) of skin sweat on the degradation and transformation mechanisms of 1-NN, as well as the skin toxicity of its transformation products. Our results show that lactic acid (LA) facilitated the photodegradation of 1-NN. The excited triplet state 1-NN ( 3 1-NN*) can oxidize LA to generate carbon-centered radicals (&#xb7;CH(CH 3 )OH) that was confirmed by EPR spin trapping and high-resolution mass spectrometry. Histidine (His) further accelerates this process by consuming dissolved oxygen ( 3 O 2 ), thereby inhibiting the quenching of 3 1-NN* as well as carbon-centered radicals by 3 O 2 . Additionally, the presence of Fe 3+ can trigger the generation of carboxyl radicals (CO 2 &#x2022;- ) via carboxylic acid ligand-to-metal charge transfer, further enhancing the photodegradation of 1-NN. Toxicity assays indicated that the photochemical transformation process of 1-NN can lead to higher cytotoxicity. These findings provide a new strategy for understanding the transformation processes and toxicity evolution of nitrated polycyclic aromatic hydrocarbons on the skin surface.

Comparative ESEM Characterization and Collagen-Related Tissue Responses to Commercial Injectable Bioregenerative Formulations in a Murine Model [PMID: 42278462 · 2026]
Marcondes APSD, Barcellos FVC, Lacerda MRP, Costa ALO, Queiroz LDRP, Oliveira JR, Milo BG, da Costa TBCR, Santos SHS, Farias LC, de Paula AMB, Guimar&#xe3;es ALS · Int J Mol Sci (2026)

Dermal senescence is associated with reduced fibroblast activity, decreased extracellular matrix synthesis, and impaired tissue repair. Commercial injectable formulations containing poly-L-lactic acid (PLLA), hyaluronic acid (HA), and polydeoxyribonucleotide (PDRN)-associated compounds have been proposed for dermal remodeling approaches and modulate tissue-response pathways; however, comparative studies evaluating commercially available formulations under standardized experimental conditions remain limited. This study aimed to characterize the morphology of formulations containing PLLA, HA, and PDRN, used alone or in combination, by environmental scanning electron microscopy (ESEM), and to investigate formulation-associated histological and collagen-related molecular responses in a murine model. Formulations containing PLLA, HA, HA + PDRN, and PLLA, HA and PDRN were administered into the dorsal subcutaneous tissue of 14 Mus musculus mice (Swiss strain). After 30 days, tissue response was assessed by ultrasound, histological analysis with Masson's trichrome staining, and RT-qPCR quantification of collagen-related gene expression. ESEM analysis revealed distinct morphological characteristics among the biomaterials, and the combined PLLA, HA and PDRN formulation exhibited a more complex and integrated multiphase structure. Histological analysis showed preserved tissue architecture in all groups, with no evidence of marked inflammatory response or structural disruption. RT-qPCR demonstrated significantly higher COL1A1 expression in the PLLA-only and PLLA, HA, and PDRN groups compared with controls ( p &lt; 0.05), whereas no significant differences were observed for COL2A1 or COL3A1. These findings indicate that PLLA-containing formulations were associated with selective COL1A1 upregulation under the evaluated conditions, suggesting formulation-associated collagen-related molecular responses in this short-term model.

Safety and Effectiveness of Two Reconstitution Volumes of Poly-L-Lactic Acid for Correction of Décolletage Wrinkles [PMID: 42235050 · 2026]
Joseph J, Palm MD, Br&#xe5;s&#xe4;ter D, Wolgast C, Weinberg F, Prygova I · J Drugs Dermatol (2026)

Aesthetic patients are increasingly aware of the contrast between rejuvenated facial skin and untreated aging skin of the d&amp;eacute;colletage, and frequently request cosmetic enhancement of this area. Poly-L-lactic acid (Sculptra&amp;reg;, Galderma; PLLA-SCA) is a regenerative biostimulator that stimulates collagen and elastin production to help regenerate the skin&amp;rsquo;s inner structure. This 9-month, open-label study investigated the effectiveness and safety of correcting d&amp;eacute;colletage wrinkles with PLLA-SCA using 2 reconstitution volumes. Women with moderate/severe wrinkles on the Galderma D&amp;eacute;colletage Scale (GDS) were randomized 1:1 to receive PLLA-SCA reconstituted with 8 mL or 17 mL sterile water for injection, plus 1 mL 2% lidocaine (up to 4 treatments, 1 month apart). Assessments included GDS, Global Aesthetic Improvement Scale (GAIS), subject satisfaction, skin quality, and adverse events (AEs). Of 30 randomized subjects, the majority (8 mL: 93.8%; 17 mL: 78.6%) showed a &amp;ge;1-point improvement on investigator-assessed GDS at month 9 (primary endpoint), with &amp;ge;93% improved also at month 6. GAIS improvement was also great (&amp;gt;90% of subjects) across both groups at months 6 and 9. In both groups, &amp;gt;90% of subjects reported satisfaction with the appearance of their wrinkles by month 3, and this satisfaction was sustained throughout the study. The majority (&amp;gt;80%) of subjects were satisfied with the texture, smoothness, and radiance of their skin at months 6 and 9. One AE was judged as treatment-related; no AEs were serious or led to discontinuation. Treatment of the d&amp;eacute;colletage area with PLLA-SCA was effective and well tolerated with both reconstitution volumes, with high subject satisfaction.

Poly-l-Lactic Acid as a Regenerative Treatment for the Glucagon-like Peptide-1 Receptor Agonist User Population [PMID: 42210881 · 2026]
Franco J, Aguilera SB, Le JH, Brasater D, Nicodeme E, Meckfessel MH · Dermatol Surg (2026)

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) used for weight management have introduced unintended facial changes only partially addressed by conventional volumizing fillers. Evaluate the mechanistic rationale and clinical evidence supporting poly-l-lactic acid Sculptra (PLLA-SCA) as a biostimulatory and regenerative treatment for GLP-1 RA-associated facial changes. This narrative review synthesizes mechanistic and clinical data alongside expert opinion regarding PLLA-SCA for GLP-1 RA-driven weight loss, focusing on its biostimulatory and regenerative effects across skin layers. Poly-l-lactic acid Sculptra induces fibroblast recruitment and stimulates regeneration of collagen and elastin, and effects vasculature and adipose tissue, resulting in durable improvements in skin quality, elasticity, facial contour, and perceived age that persist for 2 years or longer. Clinical studies and real-world experiences demonstrate clinically meaningful corrections of midface and perioral volume loss, jawline contour, and radiance, including in patients with GLP-1 RA-related facial changes. Poly-l-lactic acid Sculptra may help address GLP-1 RA-associated facial atrophy by supporting long-term regeneration and restoration of facial definition, contour, and skin quality. The effects potentially extend across all 3 skin layers affected by the GLP-1 RA phenotype, including atrophy and gauntness. Poly-L-lactic acid Sculptra offers clinicians an option to deliver durable regenerative treatment that helps restore facial aesthetics in this patient population.

Type 1 Collagen/Poly-L-Lactic Acid Biocomposite Augmentation of a Nontraumatic Symptomatic Complete Rotator Cuff Tear [PMID: 42311585 · 2026]
Wilder JH, Willard J, Schoofs E, Bennett B, Jacobs G, Laurent J, Jones D · Ochsner J (2026)

Treatment modalities for rotator cuff tears are continuously evolving. Augmentation of rotator cuff repair with biocomposite implants with bioinductive properties such as collagen scaffolds, dermal grafts, and synthetic materials are increasingly being used to ensure repair integrity. Ideally, an implant should provide added structural integrity as well as biologic components that augment the final repair tissue quality. A 69-year-old male underwent arthroscopic rotator cuff repair augmented with a BioBrace Reinforced BioInductive Implant (CONMED Corporation), a biocomposite implant containing type 1 bovine collagen with poly-L-lactic acid. With physical therapy, the patient's periscapular and rotator cuff strengthening had progressed by 8 weeks postoperatively, and full return to activities began at 6 months postoperatively. Postoperative magnetic resonance imaging at 1 year demonstrated complete healing of the rotator cuff repair with intact footprint on coronal and sagittal images. This biocomposite implant provides an encouraging option for use in patients with poor tissue quality or tear patterns that are concerning for possible postoperative retear.

VectorLift: Anatomically Guided Thread-Lifting Technique With Reduced Pain and Downtime - Results from a Real-World Non-Randomized Comparative Study [PMID: 42299445 · 2026]
Leguina-Ruzzi A, Rawshani N, Brito S, Bin BH, Abbas Z, Zhao Q · Clin Cosmet Investig Dermatol (2026)

Thread lifting has emerged as a minimally invasive alternative to surgical facial rejuvenation, providing mechanical tissue repositioning with shorter recovery times. Advances in biomaterials and thread design have improved safety and lifting capacity; however, variability in clinical outcomes persists due to differences in vector design, thread type, tissue manipulation, and anesthesia techniques. These factors may influence complication rates, procedural tolerance, and postoperative downtime, contributing to ongoing concerns regarding the predictability and reproducibility of thread-lifting procedures. To describe the development of a vector-optimized thread-lifting technique (VectorLift) and to compare its clinical performance in an exploratory, real-world, non-randomized comparative study with two commonly used thread-lifting approaches employing different biomaterials and insertion methods. The VectorLift protocol was developed using anatomically guided vector placement, ligament-oriented reinforcement, and optimized local anesthetic infiltration. Over a three-year period, 44 female patients (mean age 47 years) underwent facial thread-lifting procedures. Eighteen patients were treated using the proposed technique with cannulated polydioxanone (PDO) threads, while the remaining patients were treated with either double-needle poly-L-lactic acid (PLA) plus poly(L-lactide-co-glycolide) (PLGA) cone threads or cannulated PLA/polycaprolactone (PCL) threads. Clinical outcomes included recovery time (days of downtime), intraoperative pain levels, patient satisfaction measured using the FACE-Q scale before treatment and two weeks post-procedure, and complication rates including dimpling, bruising, edema, and transient asymmetry. Standardized clinical photographs were obtained before and immediately after treatment. VectorLift was associated with lower reported intraoperative pain, shorter recovery time and lower rates of early postoperative complications compared with the other techniques, while patient satisfaction scores were comparable among groups. Immediate photographic assessment confirmed visible aesthetic improvement without overcorrection. VectorLift is an anatomically guided thread-lifting technique that, in this real-world non-randomized comparative study, was associated with improved procedural tolerance and shorter postoperative downtime while maintaining high patient satisfaction and effective aesthetic outcomes. Further controlled studies with larger patient populations and longer follow-up periods are warranted to confirm these findings.

Longevity Aesthetics: A Conceptual Framework for Integrating Pro-Aging Medicine Into Surgical and Nonsurgical Practice [PMID: 42253424 · 2026]
Haykal D, Nahai F · Aesthet Surg J Open Forum (2026)

The prevailing paradigm in aesthetic medicine is the "antiaging" model, which focuses on correcting and/or reversing visible signs of aging. However, contemporary geroscience reconceptualizes aging as a malleable biological process driven by defined hallmarks, offering an opportunity to align aesthetic practice with the fundamental aging biology. This article explores the concept of "pro-aging" or "longevity aesthetics," a framework that prioritizes tissue function, resilience, and biological integrity alongside phenotypic improvement. The skin is presented as an accessible model organ that reflects key hallmarks of aging and their clinical manifestations. Although conventional aesthetic interventions effectively address structural changes, they often do not target upstream biological drivers of tissue aging. Within this framework, certain surgical and nonsurgical modalities may theoretically support tissue resilience through modulation of inflammation, collagen remodeling, and microvascular health. Importantly, some of these strategies, such as biostimulatory injectables including calcium hydroxylapatite and poly-L-lactic acid, as well as combination treatment approaches, are already integrated into clinical practice, whereas others remain in the translational or research domain. Emerging concepts such as multi-omics, defined as the integration of genomics, transcriptomics, proteomics, metabolomics, and epigenomics, may further enable personalized and predictive approaches in the future. Longevity aesthetics, therefore, represents a conceptual evolution from correction to functional preservation. However, direct clinical evidence supporting its biological impact remains limited, and these concepts should currently be interpreted as hypothesis driven. Advancing this framework will require prospective studies integrating biomarkers with long-term clinical outcomes. Ultimately, this approach positions aesthetic medicine to contribute to translational geroscience, provided innovation is guided by methodological rigor and ethical transparency. Level of Evidence: 5 (Therapeutic).

Mechanisms of Cytokine Modulation and Inflammatory Cascade in Bio-stimulatory Skin Rejuvenation: A Comprehensive Literature Review of Poly-L-Lactic Acid, Calcium Hydroxyapatite, Polycaprolactone, and Poly-D, L-Lactic Acid [PMID: 42211639 · 2026]
Flores Rodr&#xed;guez JC, Rosengaus Leizgold FE, C&#xe1;rdenas Sicilia N, Porras Zamora BM, Merino Arellano R, Rico Mac&#xed;as NM, Cabello Mart&#xed;nez SS · Cureus (2026)

Biostimulatory fillers, such as poly-L-lactic acid (PLLA), poly-D,L-lactic acid (PDLLA), polycaprolactone (PCL), and calcium hydroxyapatite (CaHA), have transformed aesthetics by promoting neocollagenesis through regulated inflammatory and cytokine-driven cascades. Their clinical effectiveness is well-established, but there is a lack of a synthesis of their mechanisms of action. The proposed comprehensive narrative literature review synthesized the contemporary evidence on the cytokine-modulating mechanisms and pathways of inflammatory responses induced by PLLA, PDLLA, PCL, and CaHA. The study design is a narrative literature review, which is performed using a systematic approach based on PRISMA 2020 guidelines. As a comprehensive literature review incorporating heterogeneous and predominantly non-comparative study designs, a formal risk-of-bias assessment using standardized tools was not performed; however, study limitations were considered qualitatively. It matched the identified mechanistic processes with clinical outcomes and safety profiles. The review included 22 clinical studies published from 1stJanuary 2010 to 28th February 2026, comprising randomized controlled trials, cohort studies, and quasi-experimental designs. Extracted data were systematically categorized into six predefined domains: acute inflammatory profile, macrophage polarization, fibroblast extracellular matrix (ECM) response, angiogenesis, clinical outcomes, and adverse events based on thematic analysis of study endpoints. All four biostimulators elicit a controlled inflammatory response characterized by macrophage infiltration and, in some cases, foreign-body giant cell formation. PLLA and PDLLA promote a transition from pro-inflammatory to pro-regenerative M2 macrophage phenotypes, driving sustained upregulation of Type I and III collagen, elastin, and angiogenesis. PCL induces durable neocollagenesis lasting up to 24 months, supported by neovascularization. CaHA stimulates fibroblast activity and ECM production, with a more pronounced early inflammatory gene signature than PLLA. Clinically, all biostimulators achieve significant and sustained improvements in wrinkle severity, skin quality, and volume restoration, with high patient satisfaction rates. Adverse events were predominantly mild and transient, with nodule formation being most notable with PLLA (4.7-28.6%). The study concluded that PLLA, PDLLA, PCL, and CaHA each elicit distinct yet overlapping inflammatory and cytokine-mediated cascades that culminate in robust neocollagenesis and tissue remodeling. Understanding these mechanistic differences enables clinicians to tailor treatment selection and protocols to achieve optimal, durable aesthetic outcomes with favorable safety profiles.

Controlled release of chlorine dioxide from α-cyclodextrin complexes embedded in poly(lactic acid)/poly(butylene adipate-co-butylene terephthalate) films for sustainable food packaging [PMID: 42205557 · 2026]
He X, Tang L, Ding W, Wang Q, Liu M, Zhong T, Huang R · Food Chem X (2026)

In this study, chlorine dioxide (ClO&#x2082;) was encapsulated within &#x3b1;-cyclodextrin (&#x3b1;-CD) via two approaches: in situ ClO&#x2082; generation (EC) and effervescent tablets (ET). FTIR, XRD, TG-DTG, SEM, and water contact angle (WCA) analyses verified the successful formation of ClO&#x2082;/&#x3b1;-CD inclusion complexes and revealed distinct structural, thermal, and morphological differences between EC and ET. EC exhibited superior encapsulation efficiency (2.3% vs. 0.9% in ET), and slower ClO&#x2082; release rates across varying storage temperatures, indicating stronger host - guest interactions and more robust structural integration. Kinetic analysis confirmed that ClO&#x2082; release followed the first-order model for 1% and 5% groups and the zero-order model for the 3% group, with a non-Fickian anomalous diffusion mechanism controlled by both gas diffusion and polymer chain relaxation. The EC complex was incorporated into biodegradable PLA/PBAT composite films at varying concentrations (1-5%) to develop functional packaging materials. The incorporation of EC enhanced surface hydrophilicity but reduced tensile strength and light transmittance due to particle aggregation. At low loadings (1-3%), well-dispersed EC particles created a tortuous diffusion path and improved oxygen barrier properties. At 5% EC, excessive agglomeration induced microstructural defects and increased gas permeability, which was supported by microstructural observations. Grape preservation tests at 25&#xa0;&#xb0;C showed that PLA/PBAT/EC films effectively inhibited microbial spoilage and extended shelf life, despite a slight increase in mass loss related to higher water vapor permeability. In vitro antimicrobial evaluation against Rhizopus stolonifer further validated the concentration-dependent antibacterial activity of the films. These results highlight the potential of ClO&#x2082;/&#x3b1;-CD inclusion complexes for active food packaging applications. These results support the potential of EC-based ClO&#x2082; complexes in active packaging systems for enhanced food preservation.

Dual-mode Sequential Radiofrequency in Challenging Skin Types: Case Reports in Atopic-prone and Previously Treated Patients [PMID: 42199246 · 2026]
Lee J, Kumar N · Plast Reconstr Surg Glob Open (2026)

Facial laxity is a major aesthetic concern, often managed through energy-based skin-tightening devices. However, safety considerations arise when treating patients with atopic dermatitis (AD), due to barrier dysfunction, and in those with prior aesthetic procedures, where synergistic effects and risks remain unclear. We aimed to assess the safety and efficacy of a dual-mode radiofrequency (RF) device in 2 challenging clinical contexts: atopic-prone skin and previously treated skin. Two female patients underwent single-session treatment with a dual-mode monopolar-bipolar RF system (DENSITY, Jeisys Medical Inc., Seoul, Republic of Korea), with integrated contact cooling. Outcomes were assessed using standardized photography, patient-reported improvement, and monitoring for adverse events. Both patients exhibited clinically significant skin tightening, improved skin texture, and reduced fine lines. The patient with AD tolerated treatment without flares or complications. The previously treated patient (Ultherapy, botulinum toxin, poly-D,L-lactic acid boosters) reported complementary benefits beyond those achieved with earlier procedures. Both rated satisfaction as 4 out of 5. Treatment-related discomfort was reported as 6 out of 10 (AD patient) and 5 out of 10 (previously treated patient). Dual-mode RF seems to be safe and effective for addressing facial laxity in patients with atopic-prone skin and in those who have undergone prior aesthetic treatments. It may serve as a valuable adjunct or maintenance modality in facial rejuvenation.

자주 묻는 질문 (AEO 스니펫 최적화 FAQ)

Q1. 락틱애씨드 (LACTIC ACID)의 국가별 공식 전성분 표기명은 어떻게 다른가요?
한국 식약처 표준명은 '락틱애씨드', 미국 PCPC 및 유럽 CosIng INCI 표기는 'LACTIC ACID', 중국 NMPA IECIC 표준명은 '乳酸', 일본 화장품 표시명칭은 '乳酸'입니다.
Q2. 락틱애씨드의 글로벌 6대 권역 법정 배합 한도(Layer 1)는 무엇인가요?
한국(KR: none), 유럽(EU: none), 미국(US: none), 중국(CN: allowed), 일본(JP: none), 아세안(ASEAN: none) 고시 기준을 준수하여 처방해야 합니다.
Q3. 제형 설계 시 락틱애씨드의 통상 배합 농도(Layer 3)와 적정 pH는 얼마인가요?
대표 제형군(emulsion_cream) 기준 통상 0.1~0.9%(권장 중앙값 0.6%) 범위로 투입하며, 적정 pH는 4~8입니다.
Q4. 락틱애씨드 배합 시 주의해야 할 상용성 금기(Incompatibilities)와 시너지 성분은 무엇인가요?
주요 권장 시너지 조합은 GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL이며, 배합 주의사항은 처방 내 극단적 pH 조건 및 고농도 전해질과의 상용성 사전 확인 권장입니다.